Petros Pharmaceuticals amends Series A Preferred; maturity extended to Feb 2025, $500k cash covenant added

Petros Pharmaceuticals, Inc.

Extended maturity date of Series A Convertible Preferred Stock from prior date to February 15, 2025.
Deferred all unpaid accrued amounts under the Certificate of Designations to February 15, 2025.
Company must maintain at least $500,000 in unrestricted cash from January 15 to February 15, 2025.
Amended restrictive covenant to allow changes in sales strategy for Stendra avanafil and OTC switch platform.
Required holders waived any breach from failure to pay outstanding amounts as of January 23, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.